Product Description: VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
Formula: C68H105N11O15
References: [1]Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897./[2]Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87./[3]Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.
CAS Number: 646502-53-6
Molecular Weight: 1316.63
Compound Purity: 99.98
Research Area: Cancer
Solubility: DMSO : ≥ 54 mg/mL/Ethanol : 50 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Drug-Linker Conjugates for ADC;Microtubule/Tubulin